ViroCarb

ViroCarb is a pharmaceutical company developing antiviral drugs. They have discovered a new class of small molecules that inhibit the replication of pathogenic viruses by targeting the host (e.g., humans) cell functions used by pathogenic viruses to grow and multiply. ViroCarb’s preclinical drug candidate, GPS-491 has

ViroCarb is active in the health space.

Profile

ViroCarb is a pharmaceutical company developing antiviral drugs. They have discovered a new class of small molecules that inhibit the replication of pathogenic viruses by targeting the host (e.g., humans) cell functions used by pathogenic viruses to grow and multiply. ViroCarb’s preclinical drug candidate, GPS-491 has shown to block the replication of multiple viral families […]

Its activity falls under health; the profile below is assembled from public directory data.

The company is listed at the Creative Destruction Lab alumni company stage of development.

Website: virocarb.com